Jazz Pharmaceuticals (JAZZ) PT Lowered to $180 at Stifel
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $248.36 +1.39%
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Join SI Premium – FREE
Stifel analyst Annabel Samimy lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $180.00 (from $185.00) while maintaining a Buy rating.
You May Also Be Interested In
- Biotech funding rises 75% this year as M&A activity continues
- Candel Therapeutics Inc. (CADL) PT Raised to $15 at Freedom Broker
- JD Logistics Inc (2618:HK) (JDLGF) PT Lowered to HK$18 at Nomura/Instinet
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
